SlideShare une entreprise Scribd logo
1  sur  42
Acute rheumatic fever (ARF) is a multisystem
disease resulting from an autoimmune
reaction to infection with group A
streptococcus.
 ARF is mainly a disease of children aged 5 - 14
years
The prevalence of RHD, peaks between 25 and
40 years.
 There is no clear gender association for ARF
 RHD more commonly affects females,
twice as frequently as males.
 Organism Factors
 ARF is exclusively caused by infection of
the upper respiratory tract with group A
streptococci .
 Classically, certain M-serotypes (types 1, 3, 5,
6, 14, 18, 19, 24, 27, and 29) in high-incidence
regions
 Familial clustering of cases and concordance in
monozygotic twins—particularly for chorea—
confirm that susceptibility to ARF is an inherited
characteristic.
 (HLA) class II alleles appear to be strongly
associated with susceptibility.
 High levels of circulating mannose-binding lectin
and polymorphisms of transforming growth
factor 1 gene.

 Because of the similarity btw hyaluronic acid
in GAS capsule and in the connective tissue of
the joints, Ab produced against GAS capsule
will start to attack the joints and causes
arthritis.
 M-protein in GAS cell wall and the
myocardium are similar, thus Ab produced
against GAS cell wall will attack heart and will
cause carditis and so forth.
 Similarly Ab against NAG in GAS will affect
 When a susceptible host encounters a group A
streptococcus, an autoimmune reaction results, which
leads to damage to human tissues as a result of cross-
reactivity between epitopes on the organism and the host
Cross-reactive epitopes are present in the streptococcal M
protein and the N-acetylglucosamine of group A
streptococcal carbohydrate and are immunologically
similar to molecules in human myosin, tropomyosin,
keratin, actin, laminin, vimentin, and N-
acetylglucosamine. It is currently thought that the initial
damage is due to cross-reactive antibodies attaching at
the cardiac valve endothelium, allowing the entry of
primed CD4+ T cells, leading to subsequent T cell-
mediated inflammation.
 There is a latent period of 3 weeks (1–5
weeks) between the streptococcal infection
and the appearance of the clinical features of
ARF.
 The exceptions are chorea and indolent
carditis, which may follow prolonged latent
periods lasting up to 6 months.
 The most common clinical presentation of
ARF is polyarthritis and fever.
 Polyarthritis is present in 60–75% of cases
and carditis in 50–60%.
 The prevalence of chorea in ARF varies <2%
to 30%.
 Erythema marginatum and subcutaneous
nodules are now rare, being found in <5% of
case
 Up to 60% of patients with ARF progress to RHD.
 The endocardium, pericardium, or myocardium may
be affected.
 Valvular damage is the hallmark of rheumatic carditis.
 The mitral valve is almost always affected,
sometimes together with the aortic valve; isolated
aortic valve involvement is rare.
 Early valvular damage leads to regurgitation.
 Therefore the characteristic manifestation of
carditis in previously unaffected individuals is
MR, sometimes accompanied by AR .
 First-degree AV block
 Softening of the first heart sound
 The typical arthritis is migratory, moving from
one joint to another over a period of hours. ARF
almost always affects the large joints—most
commonly the knees, ankles, hips, and elbows—
and is asymmetric.
 Aseptic monoarthritis
 The joint manifestations are highly responsive to
salicylates and other nonsteroidal anti-
inflammatory drugs (NSAIDs).
 Follows a prolonged latent period after
group A streptococcal infection, and is found
mainly in females.
 The choreiform movements affect
particularly the head and the upper limbs .
 Chorea eventually resolves completely
usually within 6 weeks
 The classic rash of ARF is erythema
marginatum
 Pink macules that clear centrally, leaving a
serpiginous, spreading edge. The rash is
evanescent, appearing and disappearing
before the examiner's eyes. It occurs usually
on the trunk, sometimes on the limbs, but
almost never on the face.
 Subcutaneous nodules occur as painless, small
(0.5–2 cm), mobile lumps beneath the skin
overlying bony prominences, particularly of
the hands, feet, elbows, occiput, and
occasionally the vertebrae.
 They are a delayed manifestation, appearing
3 weeks after the onset of disease, and are
commonly associated with carditis.
 Fever occurs in most cases of ARF, although
rarely in cases of pure chorea.
 Elevated acute-phase reactants are also
present in most cases. ,C-reactive protein
(CRP) and erythrocyte sedimentation rate
(ESR) are often dramatically elevated.
Occasionally the peripheral leukocyte count
is mildly elevated.
 anti-streptolysin O (ASO) and anti-DNase B
(ADB) titers.
 Post-streptococcal reactive arthritis (PSRA) is
(1) small-joint involvement that is often
symmetric;
 (2) a short latent period following
streptococcal infection (usually <1 week);
 (3) occasional causation by nongroup A
-hemolytic streptococcal infection;
 (4) slower responsiveness to salicylates;
 (5) the absence of other features of ARF,
particularly carditis.
 Pediatric autoimmune neuropsychiatric
disorders associated with streptococcal infection
(PANDAS) is a term that links a range of tic
disorders and obsessive-compulsive symptoms
with group A streptococcal infections. People
with PANDAS are said not to be at risk of
carditis, unlike patients with Sydenham's
chorea. The diagnoses of PANDAS and PSRA
should rarely be made in populations with a high
incidence of ARF.
MAJOR CRITERIA
1. Carditis
2. Arthritis
3. Subcutaneous nodules
4. Erythema marginatum
5. Chorea
CLINICAL
1. Fever
2. Arthralgia
3. Previous h/o rheumatic fever
LABORATORY
1. Acute phase reactants
2. PR prolongation
Evidence of recent streptococcal infection
evidenced by
1. Increase in ASO
2. Positive throat culture for streptococcal
infection
3. Recent history of scarlet fever
4. Rapid antigen test for group A streptococcus
 2 major / 1 major and 2 minor in the
presence of essential criteria.
DIAGNOSTIC CATEOGORIES CRITERIA
Primary episode of rheumatic fever Two major or one major and two minor
manifestations plus evidence of preceding
group A streptococcal infection
Recurrent attack of rheumatic fever in a
patient without established rheumatic heart
disease
Two major or one major and two minor
manifestations plus evidence of preceding
group A streptococcal infection
Recurrent attack of rheumatic fever in a
patient with established rheumatic heart
disease
Two minor manifestations plus evidence of
preceding group A streptococcal infectionc
Rheumatic chorea Insidious onset rheumatic
carditis
Other major manifestations or evidence of
group A streptococcal infection not required
Chronic valve lesions of rheumatic heart
disease (patients presenting for the first
time with pure mitral stenosis or mixed
mitral valve disease and/or aortic valve
disease)
Do not require any other criteria to be
diagnosed as having rheumatic heart
disease

Recommended for all cases
 White blood cell count
 Erythrocyte sedimentation rate
 C-reactive protein
 Blood cultures if febrile
 Electrocardiogram
 Chest x-ray if clinical or echocardiographic evidence of carditis
 Echocardiogram (consider repeating after 1 month if negative)
 Throat swab (preferably before giving antibiotics)–culture for
group A streptococcus
 Anti-streptococcal serology: both anti-streptolysin O and anti-
DNase B titres, if available (repeat 10–14 days later if 1st test not
confirmatory)
 Tests for alternative diagnoses, depending on
clinical features
 Repeated blood cultures if possible
endocarditis
 Joint aspirate (microscopy and culture) for
possible septic arthritis
 Copper, ceruloplasmin, anti-nuclear antibody,
drug screen for choreiform movements
 Serology and auto-immune markers for
arboviral, auto-immune or reactive arthritis
 Penicillin is the drug of choice and can be
given orally [as phenoxymethyl penicillin, 500
mg (250 mg for children< 27 kg) PO twice
daily, or amoxicillin 50 mg/kg (max 1 g) daily,
for 10 days] or as a single dose of 1.2 million
units (600,000 units for children 27 kg) IM
benzathine penicillin G.
 Aspirin is the drug of choice. An initial dose of 80–100
mg/kg per day in children (4–8 g/d in adults) in 4–5
divided doses is often needed for the first few days up
to 2 weeks.
 When the acute symptoms are substantially resolved,
the dose can be reduced to 60–70 mg/kg per day for a
further 2–4 weeks.
 Naproxen at a dose of 10–20 mg/kg per day has been
reported to lead to good symptomatic response.
Cases of severe carditis (causing heart failure)
with glucocorticoids in the belief that they
may reduce the acute inflammation and
result in more rapid resolution of failure.
Prednisone or prednisolone are recommended
at doses of 1–2 mg/kg per day (maximum, 80
mg). Glucocorticoids are often only required
for a few days or up to a maximum of 3 weeks
 Carbamazepine
 Sodium valproate
 Intravenous Immunoglobulin (Ivig)
 Primary Prevention
 Avoid overcrowded housing.
 Mainstay of primary prevention for ARF
remains primary prophylaxis (i.e., the timely
and complete treatment of group A
streptococcal sore throat with antibiotics
 Oral penicillin V (250 mg) can be given twice-
daily
 Benzathine penicillin G (1.2 million units, or
600,000 units if <27 kg) delivered every 4
weeks.
 Erythromycin (250 mg) twice daily.
Category of Patient Duration of Prophylaxis
Rheumatic fever without carditis For 5 years after the last attack or 21 years of a
(whichever is longer
Rheumatic fever with carditis but no residual
valvular disease
For 10 years after the last attack, or 21 years o
age (whichever is longer
Rheumatic fever with persistent valvular disease,
evident clinically or on echocardiography
For 10 years after the last attack, or 40 years o
age (whichever is longer). Sometimes lifelong
prophylaxis
Acute rheumatic fever

Contenu connexe

Tendances

Rheumatic fever & acute rheumatic heart disease Rheumatic fever & acute rhe...
Rheumatic fever & acute rheumatic heart disease 	 Rheumatic fever & acute rhe...Rheumatic fever & acute rheumatic heart disease 	 Rheumatic fever & acute rhe...
Rheumatic fever & acute rheumatic heart disease Rheumatic fever & acute rhe...
MedicineAndFamily
 
Rheumatic fever and heart disease
Rheumatic fever and heart diseaseRheumatic fever and heart disease
Rheumatic fever and heart disease
Swapna Pillai
 
INTERNAL MEDICINE - Secondary Hypertension
INTERNAL MEDICINE - Secondary HypertensionINTERNAL MEDICINE - Secondary Hypertension
INTERNAL MEDICINE - Secondary Hypertension
Nian Baring
 
Acute rheumatic fever ppt final copy
Acute rheumatic fever ppt final copyAcute rheumatic fever ppt final copy
Acute rheumatic fever ppt final copy
JAYDIP NINAMA
 

Tendances (20)

Infective endocarditis
Infective endocarditis Infective endocarditis
Infective endocarditis
 
Acute rheumatic fever
Acute rheumatic feverAcute rheumatic fever
Acute rheumatic fever
 
Rheumatic fever
Rheumatic feverRheumatic fever
Rheumatic fever
 
Acute rheumatic fever in Children
Acute rheumatic fever in ChildrenAcute rheumatic fever in Children
Acute rheumatic fever in Children
 
Infective endocarditis
Infective endocarditisInfective endocarditis
Infective endocarditis
 
Rheumatic fever ppt
Rheumatic fever pptRheumatic fever ppt
Rheumatic fever ppt
 
Acute rheumatic fever &amp; rheumatic heart disease
Acute rheumatic fever &amp; rheumatic heart diseaseAcute rheumatic fever &amp; rheumatic heart disease
Acute rheumatic fever &amp; rheumatic heart disease
 
Rheumatic fever & acute rheumatic heart disease Rheumatic fever & acute rhe...
Rheumatic fever & acute rheumatic heart disease 	 Rheumatic fever & acute rhe...Rheumatic fever & acute rheumatic heart disease 	 Rheumatic fever & acute rhe...
Rheumatic fever & acute rheumatic heart disease Rheumatic fever & acute rhe...
 
Rheumatic fever and heart disease
Rheumatic fever and heart diseaseRheumatic fever and heart disease
Rheumatic fever and heart disease
 
Acute rheumatic fever
Acute rheumatic feverAcute rheumatic fever
Acute rheumatic fever
 
Rheumatic heart disease
Rheumatic heart diseaseRheumatic heart disease
Rheumatic heart disease
 
INTERNAL MEDICINE - Secondary Hypertension
INTERNAL MEDICINE - Secondary HypertensionINTERNAL MEDICINE - Secondary Hypertension
INTERNAL MEDICINE - Secondary Hypertension
 
Acute rheumatic fever ppt final copy
Acute rheumatic fever ppt final copyAcute rheumatic fever ppt final copy
Acute rheumatic fever ppt final copy
 
Rheumatic Heart Disease
Rheumatic Heart DiseaseRheumatic Heart Disease
Rheumatic Heart Disease
 
Infective endocarditis
Infective endocarditisInfective endocarditis
Infective endocarditis
 
Rheumatic fever
Rheumatic feverRheumatic fever
Rheumatic fever
 
Acute rheumatic fever
Acute rheumatic feverAcute rheumatic fever
Acute rheumatic fever
 
Vasculitis
VasculitisVasculitis
Vasculitis
 
Complications of acute mi
Complications of acute miComplications of acute mi
Complications of acute mi
 
Acute Rheumatic Fever
Acute Rheumatic FeverAcute Rheumatic Fever
Acute Rheumatic Fever
 

Similaire à Acute rheumatic fever

Medicine Infectious
Medicine InfectiousMedicine Infectious
Medicine Infectious
opau6suj
 
2.2. Acute Rheumatic Fever.ppt
2.2. Acute Rheumatic Fever.ppt2.2. Acute Rheumatic Fever.ppt
2.2. Acute Rheumatic Fever.ppt
AmareDejene
 
Acute rheumatic fever
Acute  rheumatic feverAcute  rheumatic fever
Acute rheumatic fever
drsharan77
 
RheumaticFever (1).ppt
RheumaticFever (1).pptRheumaticFever (1).ppt
RheumaticFever (1).ppt
AaryaJotkar
 
Lecture 6-Rheumatic Heart Diseaseff.pptx
Lecture 6-Rheumatic Heart Diseaseff.pptxLecture 6-Rheumatic Heart Diseaseff.pptx
Lecture 6-Rheumatic Heart Diseaseff.pptx
nabidiana0213
 
management of acute rheumatic fever
management of acute rheumatic fevermanagement of acute rheumatic fever
management of acute rheumatic fever
Basem Enany
 

Similaire à Acute rheumatic fever (20)

Rheumatic fever
Rheumatic feverRheumatic fever
Rheumatic fever
 
10.Rheumatic Fever.ppt
10.Rheumatic Fever.ppt10.Rheumatic Fever.ppt
10.Rheumatic Fever.ppt
 
Rheumatic fever and Rheumatic heart disease
Rheumatic fever and Rheumatic heart diseaseRheumatic fever and Rheumatic heart disease
Rheumatic fever and Rheumatic heart disease
 
Rheumatic fever 1.pptx
Rheumatic fever 1.pptxRheumatic fever 1.pptx
Rheumatic fever 1.pptx
 
Rheumatic fever - all you need to know
Rheumatic fever - all you need to knowRheumatic fever - all you need to know
Rheumatic fever - all you need to know
 
Acute rheumatic fever
Acute rheumatic feverAcute rheumatic fever
Acute rheumatic fever
 
Medicine Infectious
Medicine InfectiousMedicine Infectious
Medicine Infectious
 
Samir rafla principles of cardiology pages 1 61
Samir rafla principles of cardiology pages 1 61 Samir rafla principles of cardiology pages 1 61
Samir rafla principles of cardiology pages 1 61
 
2.2. Acute Rheumatic Fever.ppt
2.2. Acute Rheumatic Fever.ppt2.2. Acute Rheumatic Fever.ppt
2.2. Acute Rheumatic Fever.ppt
 
Acute rheumatic fever.ppt
Acute rheumatic fever.pptAcute rheumatic fever.ppt
Acute rheumatic fever.ppt
 
3 arf (2)
3 arf (2)3 arf (2)
3 arf (2)
 
Acute rheumatic fever
Acute  rheumatic feverAcute  rheumatic fever
Acute rheumatic fever
 
RheumaticFever.ppt
RheumaticFever.pptRheumaticFever.ppt
RheumaticFever.ppt
 
RheumaticFever (1).ppt
RheumaticFever (1).pptRheumaticFever (1).ppt
RheumaticFever (1).ppt
 
K rheumatic fever-yds
K rheumatic fever-ydsK rheumatic fever-yds
K rheumatic fever-yds
 
Acute rheumatic fever
Acute   rheumatic    feverAcute   rheumatic    fever
Acute rheumatic fever
 
Arf
ArfArf
Arf
 
Lecture 6-Rheumatic Heart Diseaseff.pptx
Lecture 6-Rheumatic Heart Diseaseff.pptxLecture 6-Rheumatic Heart Diseaseff.pptx
Lecture 6-Rheumatic Heart Diseaseff.pptx
 
Acute rheumatic fever-definition,pathophysiology,clinical presentation and ma...
Acute rheumatic fever-definition,pathophysiology,clinical presentation and ma...Acute rheumatic fever-definition,pathophysiology,clinical presentation and ma...
Acute rheumatic fever-definition,pathophysiology,clinical presentation and ma...
 
management of acute rheumatic fever
management of acute rheumatic fevermanagement of acute rheumatic fever
management of acute rheumatic fever
 

Dernier

Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
ciinovamais
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
heathfieldcps1
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
PECB
 

Dernier (20)

Role Of Transgenic Animal In Target Validation-1.pptx
Role Of Transgenic Animal In Target Validation-1.pptxRole Of Transgenic Animal In Target Validation-1.pptx
Role Of Transgenic Animal In Target Validation-1.pptx
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
Measures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDMeasures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SD
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
psychiatric nursing HISTORY COLLECTION .docx
psychiatric  nursing HISTORY  COLLECTION  .docxpsychiatric  nursing HISTORY  COLLECTION  .docx
psychiatric nursing HISTORY COLLECTION .docx
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docx
 

Acute rheumatic fever

  • 1.
  • 2. Acute rheumatic fever (ARF) is a multisystem disease resulting from an autoimmune reaction to infection with group A streptococcus.
  • 3.
  • 4.  ARF is mainly a disease of children aged 5 - 14 years The prevalence of RHD, peaks between 25 and 40 years.  There is no clear gender association for ARF  RHD more commonly affects females, twice as frequently as males.
  • 5.  Organism Factors  ARF is exclusively caused by infection of the upper respiratory tract with group A streptococci .  Classically, certain M-serotypes (types 1, 3, 5, 6, 14, 18, 19, 24, 27, and 29) in high-incidence regions
  • 6.  Familial clustering of cases and concordance in monozygotic twins—particularly for chorea— confirm that susceptibility to ARF is an inherited characteristic.  (HLA) class II alleles appear to be strongly associated with susceptibility.  High levels of circulating mannose-binding lectin and polymorphisms of transforming growth factor 1 gene. 
  • 7.
  • 8.
  • 9.  Because of the similarity btw hyaluronic acid in GAS capsule and in the connective tissue of the joints, Ab produced against GAS capsule will start to attack the joints and causes arthritis.  M-protein in GAS cell wall and the myocardium are similar, thus Ab produced against GAS cell wall will attack heart and will cause carditis and so forth.  Similarly Ab against NAG in GAS will affect
  • 10.  When a susceptible host encounters a group A streptococcus, an autoimmune reaction results, which leads to damage to human tissues as a result of cross- reactivity between epitopes on the organism and the host Cross-reactive epitopes are present in the streptococcal M protein and the N-acetylglucosamine of group A streptococcal carbohydrate and are immunologically similar to molecules in human myosin, tropomyosin, keratin, actin, laminin, vimentin, and N- acetylglucosamine. It is currently thought that the initial damage is due to cross-reactive antibodies attaching at the cardiac valve endothelium, allowing the entry of primed CD4+ T cells, leading to subsequent T cell- mediated inflammation.
  • 11.  There is a latent period of 3 weeks (1–5 weeks) between the streptococcal infection and the appearance of the clinical features of ARF.  The exceptions are chorea and indolent carditis, which may follow prolonged latent periods lasting up to 6 months.
  • 12.  The most common clinical presentation of ARF is polyarthritis and fever.  Polyarthritis is present in 60–75% of cases and carditis in 50–60%.  The prevalence of chorea in ARF varies <2% to 30%.  Erythema marginatum and subcutaneous nodules are now rare, being found in <5% of case
  • 13.  Up to 60% of patients with ARF progress to RHD.  The endocardium, pericardium, or myocardium may be affected.  Valvular damage is the hallmark of rheumatic carditis.  The mitral valve is almost always affected, sometimes together with the aortic valve; isolated aortic valve involvement is rare.  Early valvular damage leads to regurgitation.
  • 14.  Therefore the characteristic manifestation of carditis in previously unaffected individuals is MR, sometimes accompanied by AR .  First-degree AV block  Softening of the first heart sound
  • 15.  The typical arthritis is migratory, moving from one joint to another over a period of hours. ARF almost always affects the large joints—most commonly the knees, ankles, hips, and elbows— and is asymmetric.  Aseptic monoarthritis  The joint manifestations are highly responsive to salicylates and other nonsteroidal anti- inflammatory drugs (NSAIDs).
  • 16.  Follows a prolonged latent period after group A streptococcal infection, and is found mainly in females.  The choreiform movements affect particularly the head and the upper limbs .  Chorea eventually resolves completely usually within 6 weeks
  • 17.  The classic rash of ARF is erythema marginatum  Pink macules that clear centrally, leaving a serpiginous, spreading edge. The rash is evanescent, appearing and disappearing before the examiner's eyes. It occurs usually on the trunk, sometimes on the limbs, but almost never on the face.
  • 18.
  • 19.  Subcutaneous nodules occur as painless, small (0.5–2 cm), mobile lumps beneath the skin overlying bony prominences, particularly of the hands, feet, elbows, occiput, and occasionally the vertebrae.  They are a delayed manifestation, appearing 3 weeks after the onset of disease, and are commonly associated with carditis.
  • 20.
  • 21.  Fever occurs in most cases of ARF, although rarely in cases of pure chorea.  Elevated acute-phase reactants are also present in most cases. ,C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are often dramatically elevated. Occasionally the peripheral leukocyte count is mildly elevated.
  • 22.  anti-streptolysin O (ASO) and anti-DNase B (ADB) titers.
  • 23.  Post-streptococcal reactive arthritis (PSRA) is (1) small-joint involvement that is often symmetric;  (2) a short latent period following streptococcal infection (usually <1 week);  (3) occasional causation by nongroup A -hemolytic streptococcal infection;  (4) slower responsiveness to salicylates;  (5) the absence of other features of ARF, particularly carditis.
  • 24.  Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) is a term that links a range of tic disorders and obsessive-compulsive symptoms with group A streptococcal infections. People with PANDAS are said not to be at risk of carditis, unlike patients with Sydenham's chorea. The diagnoses of PANDAS and PSRA should rarely be made in populations with a high incidence of ARF.
  • 25. MAJOR CRITERIA 1. Carditis 2. Arthritis 3. Subcutaneous nodules 4. Erythema marginatum 5. Chorea
  • 26. CLINICAL 1. Fever 2. Arthralgia 3. Previous h/o rheumatic fever LABORATORY 1. Acute phase reactants 2. PR prolongation
  • 27. Evidence of recent streptococcal infection evidenced by 1. Increase in ASO 2. Positive throat culture for streptococcal infection 3. Recent history of scarlet fever 4. Rapid antigen test for group A streptococcus
  • 28.  2 major / 1 major and 2 minor in the presence of essential criteria.
  • 29. DIAGNOSTIC CATEOGORIES CRITERIA Primary episode of rheumatic fever Two major or one major and two minor manifestations plus evidence of preceding group A streptococcal infection Recurrent attack of rheumatic fever in a patient without established rheumatic heart disease Two major or one major and two minor manifestations plus evidence of preceding group A streptococcal infection Recurrent attack of rheumatic fever in a patient with established rheumatic heart disease Two minor manifestations plus evidence of preceding group A streptococcal infectionc Rheumatic chorea Insidious onset rheumatic carditis Other major manifestations or evidence of group A streptococcal infection not required
  • 30. Chronic valve lesions of rheumatic heart disease (patients presenting for the first time with pure mitral stenosis or mixed mitral valve disease and/or aortic valve disease) Do not require any other criteria to be diagnosed as having rheumatic heart disease
  • 31.  Recommended for all cases  White blood cell count  Erythrocyte sedimentation rate  C-reactive protein  Blood cultures if febrile  Electrocardiogram  Chest x-ray if clinical or echocardiographic evidence of carditis  Echocardiogram (consider repeating after 1 month if negative)  Throat swab (preferably before giving antibiotics)–culture for group A streptococcus  Anti-streptococcal serology: both anti-streptolysin O and anti- DNase B titres, if available (repeat 10–14 days later if 1st test not confirmatory)
  • 32.  Tests for alternative diagnoses, depending on clinical features  Repeated blood cultures if possible endocarditis  Joint aspirate (microscopy and culture) for possible septic arthritis  Copper, ceruloplasmin, anti-nuclear antibody, drug screen for choreiform movements  Serology and auto-immune markers for arboviral, auto-immune or reactive arthritis
  • 33.  Penicillin is the drug of choice and can be given orally [as phenoxymethyl penicillin, 500 mg (250 mg for children< 27 kg) PO twice daily, or amoxicillin 50 mg/kg (max 1 g) daily, for 10 days] or as a single dose of 1.2 million units (600,000 units for children 27 kg) IM benzathine penicillin G.
  • 34.  Aspirin is the drug of choice. An initial dose of 80–100 mg/kg per day in children (4–8 g/d in adults) in 4–5 divided doses is often needed for the first few days up to 2 weeks.  When the acute symptoms are substantially resolved, the dose can be reduced to 60–70 mg/kg per day for a further 2–4 weeks.  Naproxen at a dose of 10–20 mg/kg per day has been reported to lead to good symptomatic response.
  • 35. Cases of severe carditis (causing heart failure) with glucocorticoids in the belief that they may reduce the acute inflammation and result in more rapid resolution of failure. Prednisone or prednisolone are recommended at doses of 1–2 mg/kg per day (maximum, 80 mg). Glucocorticoids are often only required for a few days or up to a maximum of 3 weeks
  • 36.  Carbamazepine  Sodium valproate  Intravenous Immunoglobulin (Ivig)
  • 37.  Primary Prevention  Avoid overcrowded housing.
  • 38.  Mainstay of primary prevention for ARF remains primary prophylaxis (i.e., the timely and complete treatment of group A streptococcal sore throat with antibiotics
  • 39.  Oral penicillin V (250 mg) can be given twice- daily
  • 40.  Benzathine penicillin G (1.2 million units, or 600,000 units if <27 kg) delivered every 4 weeks.  Erythromycin (250 mg) twice daily.
  • 41. Category of Patient Duration of Prophylaxis Rheumatic fever without carditis For 5 years after the last attack or 21 years of a (whichever is longer Rheumatic fever with carditis but no residual valvular disease For 10 years after the last attack, or 21 years o age (whichever is longer Rheumatic fever with persistent valvular disease, evident clinically or on echocardiography For 10 years after the last attack, or 40 years o age (whichever is longer). Sometimes lifelong prophylaxis